Quoin Pharmaceuticals (NASDAQ: QNRX ) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide. This month, QNRX Signed Multiple Exclusive Distribution Agreements for in various regions of the globe for its Lead Asset, QRX003, for Netherton Syndrome. JMP Securities...
Yesterday, JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. (QNRX) with a Market Outperform rating and a price target of 8usd. Quoin Pharmaceuticals (NASDAQ: QNRX) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide. This month, QNRX Signed...
And has been doing so in succession for some time. Looking for zigzag completion here. We just love small caps here for their phenomenal volatility. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is...